Clinical Trial Update: Everolimus for Cancer With TSC1 or TSC2 Mutation [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating everolimus for cancers with TSC1 or TSC2 mutations has completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cancers with Tsc1 Mutation
• Cancers with Tsc2 Mutation
• Tuberous Sclerosis Complex Associated Cancers

Drugs mentioned

• Everolimus (everolimus)

Snippet

Sponsor: Dana-Farber Cancer Institute | Conditions: TSC1, TSC2 | Phase 2 | Status: COMPLETED | Results posted: 2020-09-16